Table 2 Phenotypic resistance patterns amongst clinical BHS isolates (n = 186)
| n (%) | |
|---|---|
| Inducible MLSB | 5 (2.7%) |
| Constitutive MLSB | 8 (4.3%) |
| Macrolide resistance only | 2 (1.1%) |
| Clindamycin resistance only | 3 (1.6%) |
| Macrolide–lincosamide susceptible | 168 (90.3%) |
| Total | 186 (100%) |